Dosing & Timing

EGCG is the main catechin in green tea, but dosing only makes sense when bioavailability and treatment context are taken into account.

Core issue

Most in vitro studies use concentrations that are hard to reproduce systemically with standard oral dosing. That means practical dosing discussions need to separate:

• prevention-oriented use

• adjunctive treatment support

• concentrated extract use

• beverage intake versus supplemental intake

Research dose ranges

Common supplemental study ranges often fall in the 200–800 mg/day range, with higher-dose concentrated extract use requiring more caution.

Timing considerations

• Empty-stomach use may improve absorption but may also increase liver risk with concentrated extracts

• Divided dosing may make sense because of the short half-life

• Some integrative clinicians prefer to pause EGCG around radiotherapy or oxidative chemotherapy days, then resume between cycles

• Timing should be individualised with the treatment team

Practical takeaway

There is no one universal EGCG dose for cancer. The key questions are:

• what form is being used?

• is the goal prevention, support, or active-treatment adjunctive use?

• what drugs are being taken alongside it?

• is the dose high enough to create liver or interaction concerns?

Key References

Anticancer Molecular Mechanisms of Epigallocatechin-3-Gallate (EGCG)
https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.70735

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications
https://pmc.ncbi.nlm.nih.gov/articles/PMC10343677/